# EDGAR Filing Document

**Accession Number:** 0002104204
**File Stem:** 0001193125-26-164128
**Filing Date:** 2026-4
**Character Count:** 33090
**Document Hash:** c44120f6d8c914360885af22616eac6e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-164128.hdr.sgml**: 20260420

**ACCESSION NUMBER**: 0001193125-26-164128

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260420

**DATE AS OF CHANGE**: 20260420

**EFFECTIVENESS DATE**: 20260420

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alamar Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0002104204
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364899036
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295193
- **FILM NUMBER:** 26875555

**BUSINESS ADDRESS:**
- **STREET 1:** 47071 BAYSIDE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** 510-626-9888

**MAIL ADDRESS:**
- **STREET 1:** 47071 BAYSIDE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**As filed with the Securities and Exchange Commission on April 20, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Alamar Biosciences, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **36-4899036** |
| **(State or other jurisdiction of**<br> **incorporation organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **47071 Bayside Parkway**<br> **Fremont, California** | **94538** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Alamar Biosciences, Inc. 2018 Stock Plan** 

**Alamar Biosciences, Inc. 2026 Equity Incentive Plan** 

**Alamar Biosciences, Inc. 2026 Employee Stock Purchase Plan** 

**(Full titles of the plans)** 

**Yuling Luo, Ph.D.** 

**Founder, Chairman and Chief Executive Officer** 

**Alamar Biosciences, Inc.** 

**47071 Bayside Parkway** 

**Fremont, California 94538** 

**(510) 626-9888** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Kristin VanderPas** 

**Charles S. Kim** 

**Dave Peinsipp** 

**Cooley LLP** 

**3 Embarcadero Center** 

**20th Floor** 

**San Francisco, California 94111** 

**(415) 693-2000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer, "smaller reporting company, "and "emerging growth company" in Rule 12b-2 of the Exchange Act:

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS** 

The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the "Securities Act") and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the "Commission") and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.** 

Alamar Biosciences, Inc. (the "Registrant") hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

(a) The [Registrant's prospectus](http://www.sec.gov/Archives/edgar/data/2104204/000119312526161647/d39680d424b4.htm) filed on April 17, 2026 pursuant to Rule 424(b) of the Securities Act relating to the RegistrationStatement on [Form S-1](http://www.sec.gov/Archives/edgar/data/2104204/000119312526158122/d39680ds1a.htm) , as amended (File No. 333-294697), filed with the Commission on April 16, 2026, which contains audited financial statements for the
Registrant's latest fiscal year for which such statements have been filed;

(b) The Registrant's Current Report on [Form 8-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/2104204/000119312526163921/d103481d8k.htm) (File No. 001-43235) filed with the Commission on April 20, 2026; and

(c) The description of the Registrant's Common Stock contained in the Registrant's Registration
Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/2104204/000119312526156986/d148216d8a12b.htm) filed on April 15, 2026 (File No. 001-43235) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any amendment or report filed for the purpose of updating such
description.

All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

**Item 4. Description of Securities.** 

Not applicable.

**Item 5. Interests of Named Experts and Counsel.** 

GC&H Investments, LLC, an entity comprised of partners and associates of Cooley LLP, beneficially owns an aggregate of 1,534 shares of our common stock.

------

**Item 6. Indemnification of Directors and Officers.** 

Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and executive officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant's amended and restated certificate of incorporation permits indemnification of its directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant's amended and restated bylaws provide that the Registrant will indemnify its directors and executive officers and permit it to indemnify its other officers, employees, and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law.

The Registrant has entered into, and intends to continue to enter into, separate indemnification agreements with its directors and executive officers, whereby it has agreed or will agree to indemnify its directors and executive officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or executive officer was, or is threatened to be made, a party by reason of the fact that such director or executive officer is or was a director, executive officer, employee or agent of the Registrant, provided that such director or executive officer acted in good faith and in a manner that the director or executive officer reasonably believed to be in, or not opposed to, the best interest of the Registrant. At present, there is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.

The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act, that might be incurred by any director or officer in his capacity as such.

**Item 7. Exemption from Registration Claimed.** 

Not applicable.

**Item 8. Exhibits.** 

The exhibits to this Registration Statement are listed below:

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 4.1 | [Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-43235), filed with the Commission on April 20, 2026).](http://www.sec.gov/Archives/edgar/data/2104204/000119312526163921/d103481dex31.htm) |
| 4.2 | [Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated herein by reference to Exhibit 3.4 to the Registrant's Registration Statement on Form S-1/A (File No. 333-294697), filed with the Commission on April 13, 2026).](http://www.sec.gov/Archives/edgar/data/2104204/000119312526151891/d39680dex34.htm) |
| 4.3 | [Form of Common Stock Certificate of the Registrant (incorporated herein by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1/A (File No. 333-294697), filed with the Commission on April 13, 2026).](http://www.sec.gov/Archives/edgar/data/2104204/000119312526151891/d39680dex41.htm) |
| 4.4 | [Amended and Restated Investors' Rights Agreement, by and among the Registrant and certain of its stockholders, dated February 21, 2024 (incorporated herein by reference to Exhibit 4.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-294697), filed with the Commission on March 27, 2026).](http://www.sec.gov/Archives/edgar/data/2104204/000119312526129039/d39680dex42.htm) |
| 5.1\* | [Opinion of Cooley LLP.](d123717dex51.htm) |
| 23.1\* | [Consent of Independent Registered Public Accounting Firm.](d123717dex231.htm) |
| 23.2\* | [Consent of Cooley LLP (included in Exhibit 5.1).](d123717dex51.htm) |
| 24.1\* | [Power of Attorney (included on the signature page).](#sig) |
| 99.1 | [Alamar Biosciences, Inc. 2018 Stock Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-294697), filed with the Commission on March 27, 2026).](http://www.sec.gov/Archives/edgar/data/2104204/000119312526129039/d39680dex101.htm) |

---

------

---

| | |
|:---|:---|
| 99.2 | [Forms of Stock Option Grant Notice under Alamar Biosciences, Inc. 2018 Stock Plan, as amended (incorporated by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-294697), filed with the Commission on March 27, 2026).](http://www.sec.gov/Archives/edgar/data/2104204/000119312526129039/d39680dex102.htm) |
| 99.3 | [Alamar Biosciences, Inc. 2026 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Registration Statement on Form S-1/A (File No. 333-294697), filed with the Commission on April 13, 2026).](http://www.sec.gov/Archives/edgar/data/2104204/000119312526151891/d39680dex103.htm) |
| 99.4 | [Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Alamar Biosciences, Inc. 2026 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant's Registration Statement on Form S-1/A (File No. 333-294697), filed with the Commission on April 13, 2026).](http://www.sec.gov/Archives/edgar/data/2104204/000119312526151891/d39680dex104.htm) |
| 99.5 | [Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Alamar Biosciences, Inc. 2026 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant's Registration Statement on Form S-1/A (File No. 333-294697), filed with the Commission on April 13, 2026).](http://www.sec.gov/Archives/edgar/data/2104204/000119312526151891/d39680dex105.htm) |
| 99.6 | [Alamar Biosciences, Inc. 2026 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant's Registration Statement on Form S-1/A (File No. 333-294697), filed with the Commission on April 13, 2026).](http://www.sec.gov/Archives/edgar/data/2104204/000119312526151891/d39680dex106.htm) |
| 107\* | [Filing Fee Table.](d123717dexfilingfees.htm) |

---

\* Filed herewith

------

**Item 9. Undertakings.** 

(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this
Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table
in the effective Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the
Registration Statement or any material change to such information in the Registration Statement.

*Provided, however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to
Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, California, on April 20, 2026.

---

| | |
|:---|:---|
| ALAMAR BIOSCIENCES, INC. | ALAMAR BIOSCIENCES, INC. |
| By: | /s/ Yuling Luo, Ph.D. |
|  | Yuling Luo, Ph.D. |
|  | Chief Executive Officer and President |

---

------

**POWER OF ATTORNEY** 

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Yuling Luo, Ph.D. and Justin McAnear and each of them, as his or her true and lawful attorney-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Yuling Luo, Ph.D.<br> Yuling Luo, Ph.D. | Chief Executive Officer and Director<br> (*Principal Executive Officer)* | April 20, 2026 |
| /s/ Justin McAnear<br> Justin McAnear | Chief Financial Officer<br> (*Principal Financial and Accounting Officer*) | April 20, 2026 |
| /s/ Rebecca Chambers<br> Rebecca Chambers | Director | April 20, 2026 |
| /s/ Shiping Chen, Ph.D.<br> Shiping Chen, Ph.D. | Director | April 20, 2026 |
| /s/ Nicholas Naclerio, Ph.D.<br> Nicholas Naclerio, Ph.D. | Director | April 20, 2026 |
| /s/ Ian Ratcliffe<br> Ian Ratcliffe | Director | April 20, 2026 |
| /s/ Frank R. Witney<br> Frank R. Witney | Director | April 20, 2026 |

---

## Exhibit 5.1

Exhibit 5.1

![LOGO](g123717dsp001.jpg)

David Peinsipp

+1 (415) 693-2177

dpeinsipp@cooley.com

April 20, 2026

Alamar Biosciences, Inc.

47071 Bayside Pkwy

Fremont, CA 94538

Ladies and Gentlemen:

We have acted as counsel to Alamar Biosciences, Inc., a Delaware corporation (the "***Company***"), in connection with the filing of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering by the Company of up to 14,736,374 shares (the "***Shares***") of its common stock, par value $0.0001 per share ("***Common Stock***"), consisting of (a) 6,859,974 shares of Common Stock issuable pursuant to the Company's 2018 Stock Plan (the "***2018 Plan***"), (b) 7,220,000 shares of Common Stock issuable pursuant to the Company's 2026 Equity Incentive Plan (the "***2026 Plan***") and (c) 656,400 shares of Common Stock issuable pursuant to the Company's 2026 Employee Stock Purchase Plan (together with the 2020 Plan and the 2026 Plan, the "***Plans****").*

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectuses, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the Plans and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

Cooley LLP 3 Embarcadero Center, 20<sup>th</sup> Floor, San Francisco, CA 94111-4004

t: +1 (415) 693-2000 f: +1 (415) 693-2222 cooley.com

------

![LOGO](g123717dsp001.jpg)

Alamar Biosciences, Inc.

April 20, 2026

Page Two

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| Cooley LLP | Cooley LLP |
| By: | */s/ David Peinsipp* |
| David Peinsipp | David Peinsipp |

---

Cooley LLP 3 Embarcadero Center, 20<sup>th</sup> Floor, San Francisco, CA 94111-4004

t: +1 (415) 693-2000 f: +1 (415) 693-2222 cooley.com

## Exhibit 23.1

Exhibit 23.1

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Alamar Biosciences, Inc. 2018 Stock Plan, the Alamar Biosciences, Inc. 2026 Equity Incentive Plan and the Alamar Biosciences, Inc. 2026 Employee Stock Purchase Plan of Alamar Biosciences, Inc. of our report dated March 12, 2026 (except for the effects of the reverse stock split described in Note 17, as to which the date is April 13, 2026), with respect to the consolidated financial statements of Alamar Biosciences, Inc. included in Amendment No. 2 to the Registration Statement (Form S-1 No. 333-294697) and related Prospectus filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Jose, California

April 20, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Alamar Biosciences, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.0001 par value per share, issuable upon exercise of outstanding options granted pursuant to the 2018 Stock Plan | Other | 6859974 | $4.54 | $31144281.96 | 0.0001381 | $4301.03 |
| 2 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2026 Equity Incentive Plan | Other | 5823026 | $17.00 | $98991442.00 | 0.0001381 | $13670.72 |
| 3 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2026 Employee Stock Purchase Plan | Other | 656400 | $14.45 | $9484980.00 | 0.0001381 | $1309.88 |
| 4 | Equity | Common Stock, $0.0001 par value per share, issuable upon exercise of outstanding options granted pursuant to the 2026 Equity Incentive Plan | Other | 1396974 | $17.00 | $23748558.00 | 0.0001381 | $3279.68 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $163369261.96  |  | $22561.31  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $22561.31  |

---

 **Offering Note** <br>

<sup>1</sup> (A) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Common Stock ("Common Stock") of Alamar Biosciences, Inc. (the "Registrant") that become issuable under the Registrant's 2018 Stock Plan (the "2018 Plan"), the Registrant's 2026 Equity Incentive Plan (the "2026 Plan"), or the Registrant's 2026 Employee Stock Purchase Plan (the "2026 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction. (B) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price for the 6,859,974 shares of Common Stock reserved for issuance upon the exercise of outstanding stock options granted under the 2018 Plan are calculated using the weighted-average exercise price of $4.54 per share for such stock options. (C) Represents shares of Common Stock reserved for issuance upon the exercise of outstanding stock options granted under the 2018 Plan. No additional stock awards will be granted under the 2018 Plan. The shares of common stock reserved for issuance pursuant to such stock options will become available for issuance under the 2026 Plan to the extent any such shares (i) are not issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock award having been issued, (ii) are not issued because such stock award or any portion thereof is settled in cash, (iii) are forfeited back to or repurchased by the Registrant because of the failure to meet a contingency or condition required for the vesting of such shares, (iv) are withheld or reacquired to satisfy the exercise, strike or purchase price, or (v) are withheld or reacquired to satisfy a tax withholding obligation. See footnote 2(B) below.

<sup>2</sup> (A) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are calculated on the basis of $17.00 per share (the "IPO Price"), as set forth in the Registrant's registration statement on Form S-1 (File No. 333-294697), as amended (the "S-1 Registration Statement"), that became effective on April 16, 2026. (B) Represents 5,823,026 shares of Common Stock reserved for future grant under the 2026 Plan. The 2026 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2026 Plan on January 1st of each year, commencing on January 1, 2027 and ending on (and including) January 1, 2036, in an amount equal to 5% of the total number of shares of each and every class of common stock of the Registrant outstanding on December 31 of the preceding year; provided, however, that the Board may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock. This explanation is provided for information purposes only. The issuance of such additional shares is not being registered on this Registration Statement. In addition, to the extent that any stock options outstanding under the 2018 Plan expire, terminate prior to exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price, the shares of common stock reserved for issuance pursuant to such stock options will become available for issuance under the 2026 Plan. See footnote 1(C) above.

<sup>3</sup> (A) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are calculated on the basis of the IPO Price, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the 2026 ESPP. (B) Represents 656,400 shares of Common Stock reserved for future grant under the 2026 ESPP. The 2026 ESPP provides that an additional number of shares of Common Stock will automatically be added annually to the shares authorized for issuance under the 2026 ESPP on January 1st of each year, commencing on January 1, 2027 and ending on (and including) January 1, 2036, in an amount equal to the lesser of (x) 1% of the total number of shares of each and every class of common stock of the Registrant outstanding on December 31st of the preceding calendar year, and (y) 1,969,200 shares of Common Stock; provided, however, that the Registrant's board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve for such calendar year or that the increase for such year will be a lesser number of shares of Common Stock than would otherwise occur. This explanation is provided for information purposes only. The issuance of such additional shares is not being registered on this Registration Statement.

<sup>4</sup> (A) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The amount registered represents shares of the Registrant's Common Stock that may be issued upon the exercise of outstanding options granted under the 2026 Plan. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price for the 1,396,974 shares of Common Stock reserved for issuance upon the exercise of outstanding stock options granted under the 2026 Plan are calculated using the weighted-average exercise price of $17.00 per share for such stock options.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---